The corporate is bringing the difficulty at a value band of Rs 304-321 per share at P/S a number of of approx. 4x on FY25E gross sales foundation. The corporate has the power to pioneer new applied sciences. Its E2Ws are positioned at a premium value of their respective segments within the E2W market.
We discover valuations to be nearly consistent with the corporate’s shut peer and subsequently appears to be totally priced at present stage . We additionally imagine that the difficulty’s premium itemizing to some extent may also rely upon market temper & macro scenario at the moment.
Subsequently we really feel that it may be a dangerous wager to use for a difficulty within the current surroundings & therefore we advocate to attend until itemizing earlier than deploying funds on this IPO.
(Disclaimer: Suggestions, options, views, and opinions given by specialists are their very own. These don’t signify the views of the Financial Occasions)
